Enrolling
Fecal microbiota transplantation to reduce immune activation in ART-treated people living with HIV with low CD4/CD8 ratio
Learn MoreReporting
Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People with HIV
Learn MoreReporting
A proof-of-concept study to assess the effect of recombinant human growth hormone on the size of the replication-competent viral reservoir in HIV-infected individuals on suppressive ART
Learn MoreCompleted
Impact of HIV infection and antiretroviral therapy on mucosal and systemic memory CD4 T cells
Learn MoreCompleted
Use of valproic acid to purge HIV from resting CD4+ memory cells: Trial results
Learn MoreEnrolling
Vedolizumab treatment in antiretroviral drug treated chronic HIV infection, followed by analytical treatment interruption (HIV-ART-vedolizumab-ATI)
Learn MoreCompleted
The effect of metformin on HIV reservoir size in non-diabetic ART-treated patients
Learn MoreTerminated
A pilot randomized, open label study to evaluate the effect of a therapeutic HIV vaccine consisting of PENNVAX®-GP (gag, pol, env) and INO-9012 DNA vaccine delivered via electroporation on reducing HIV viral reservoirs in infected individuals, who initiated therapy during the acute/early phase of infection
Learn MoreCompleted
Effects of HLA allele frequencies on HIV disease progression and viral load among newly diagnosed HIV infected individuals in Manitoba: Trial Results
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
